We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

214 hedge funds and large institutions have $2.82B invested in Mirum Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 76 increasing their positions, 80 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital invested

Capital invested by funds: $2.44B → $2.82B (+$375M)

1.35% more ownership

Funds ownership: 110.47%111.83% (+1.4%)

6% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 33

0% more funds holding

Funds holding: 214214 (0)

5% less repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 80

18% less funds holding in top 10

Funds holding in top 10: 119 (-2)

69% less call options, than puts

Call options by funds: $1.55M | Put options by funds: $5.06M

Holders
214
Holders Change
Holders Change %
0%
% of All Funds
2.82%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.12%
New
35
Increased
76
Reduced
80
Closed
33
Calls
$1.55M
Puts
$5.06M
Net Calls
-$3.51M
Net Calls Change
-$1.16M
Name Holding Trade Value Shares
Change
Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$25.2M +$11.1M +249,331 +101%
BNP Paribas Financial Markets
27
BNP Paribas Financial Markets
France
$24.5M -$789K -17,719 -4%
JP Morgan Chase
28
JP Morgan Chase
New York
$24.4M +$8.56M +192,340 +67%
Macquarie Group
29
Macquarie Group
Australia
$22.2M +$3.07M +68,966 +19%
Connor, Clark & Lunn Investment Management (CC&L)
30
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$21.6M +$3M +67,468 +19%
Northern Trust
31
Northern Trust
Illinois
$20.5M +$600K +13,475 +3%
Renaissance Technologies
32
Renaissance Technologies
New York
$20.2M +$9.25M +207,848 +110%
Goldman Sachs
33
Goldman Sachs
New York
$20.1M -$3.68M -82,643 -17%
Bank of America
34
Bank of America
North Carolina
$19.8M +$474K +10,648 +3%
Charles Schwab
35
Charles Schwab
California
$19.5M +$2.46M +55,282 +17%
CS
36
Candriam SCA
Luxembourg
$19M -$444K -9,974 -3%
Axa
37
Axa
France
$17.9M +$13.8K +310 +0.1%
Federated Hermes
38
Federated Hermes
Pennsylvania
$17.5M -$136K -3,062 -0.9%
PCM
39
Penn Capital Management
Pennsylvania
$17.5M -$1.39M -31,263 -8%
EA
40
Emerald Advisers
Pennsylvania
$15.6M +$13.6M +305,766 New
SCM
41
Soleus Capital Management
Connecticut
$15.2M +$13.3M +298,696 New
Millennium Management
42
Millennium Management
New York
$14.7M -$8.51M -191,140 -40%
Raymond James Financial
43
Raymond James Financial
Florida
$13.4M +$659K +14,800 +6%
EAM
44
Erste Asset Management
Austria
$13.2M
Point72 Asset Management
45
Point72 Asset Management
Connecticut
$13.2M +$1.19M +26,768 +12%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$12.7M -$468K -10,509 -4%
Russell Investments Group
47
Russell Investments Group
United Kingdom
$12.6M +$814K +18,284 +8%
Adage Capital Partners
48
Adage Capital Partners
Massachusetts
$12.4M -$4.54M -102,000 -30%
Ameriprise
49
Ameriprise
Minnesota
$12.4M +$2.09M +46,877 +24%
EP
50
Eversept Partners
New York
$11.8M +$10.3M +232,175 New

MIRM Hedge Fund Activity: Q2 2025 in Review

214 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2025, worth a combined $2.82B — up 15% from $2.44B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new MIRM positions and 33 closed out — a net gain of 2 holders — while 76 added to existing stakes and 80 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $20.9M. The largest seller was Invesco, cutting an estimated $11.1M.

  • 214 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $2.82B of Mirum Pharmaceuticals stock for Q2 2025, up 15% quarter-over-quarter.
  • 35 funds opened new Mirum Pharmaceuticals positions in Q2 2025 and 33 closed out, a net change of +2 holders.
  • The largest Mirum Pharmaceuticals buyer in Q2 2025 was Janus Henderson Group, an estimated $20.9M added.
  • The largest Mirum Pharmaceuticals seller in Q2 2025 was Invesco, an estimated $11.1M sold.

Based on aggregated 13F filings for Q2 2025.